Molecular Cancer Therapeutics · 2011 · 52 citations · 38 references
MedicineOncologyPharmacologyCancer PharmacologyImmunotherapyMolecular OncologyBreast Cancer PharmacotherapyCancer ImmunotherapyHer2-positive Breast CancerPharmacodynamics Of Anticancer AgentsTargeted Cancer TherapyTherapeutic ResistanceBreast Cancer Resistance MechanismsHer2 InhibitorsHer2-positive Breast Cancer TherapyMitogen-activated Protein Kinase SignalingProtein Kinase InhibitorsProtein TargetsTherapeutic Resistance MechanismsTrastuzumab Resistance
Hsp90 facilitates the maturation and stability of numerous oncoproteins, including HER2. The aim of this study was to assess the antitumor activity of the Hsp90 inhibitor IPI-504 in trastuzumab-resistant, HER2-overexpressing breast cancer cells. Therapy with trastuzumab, IPI-504, and the combination of trastuzumab and IPI-504 was evaluated in trastuzumab-sensitive and trastuzumab-resistant cells. Inhibition of protein targets, cell proliferation, and tumor growth was assessed in vitro and in xenograft models. IPI-504 inhibited proliferation of both trastuzumab-sensitive and trastuzumab-resistant cells. Administration of IPI-504 markedly reduced total levels of HER2 and Akt, as well as phosphorylated Akt and mitogen-activated protein kinase (MAPK), to an equal extent in trastuzumab-sensitive and trastuzumab-resistant cells. IPI-504, used as single agent or in combination with trastuzumab, also inhibited in vivo the growth of both trastuzumab-sensitive and -resistant tumor xenografts. As a mechanism for the observed antitumor activity, IPI-504 resulted in a marked decrease in the levels of HER2, Akt, p-Akt, and p-MAPK in trastuzumab-resistant xenografts as early as 12 hours after a single dose of IPI-504. IPI-504-mediated Hsp90 inhibition may represent a novel therapeutic approach in trastuzumab refractory HER2-positive breast cancer.
38
Dennis J. Slamon, Gary M. Clark, Steven Wong et al. · Science · 1987 · 11.7K citations
Studies of the HER-2/ <i>neu</i> Proto-Oncogene in Human Breast and Ovarian Cancer
Dennis J. Slamon, William Godolphin, Lovell A. Jones et al. · Science · 1989 · 6.9K citations
Melody Cobleigh, Charles L. Vogel, Debu Tripathy et al. · Journal of Clinical Oncology · 1999 · 2.8K citations
Medicine, Oncology, Pharmacology +17